Literature DB >> 19426212

CD28 and CTLA-4 coreceptor expression and signal transduction.

Christopher E Rudd1, Alison Taylor, Helga Schneider.   

Abstract

SUMMARY: T-cell activation is mediated by antigen-specific signals from the TCRzeta/CD3 and CD4-CD8-p56lck complexes in combination with additional co-signals provided by coreceptors such as CD28, inducible costimulator (ICOS), cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death (PD-1), and others. CD28 and ICOS provide positive signals that promote and sustain T-cell responses, while CTLA-4 and PD-1 limit responses. The balance between stimulatory and inhibitory co-signals determines the ultimate nature of T-cell responses where response to foreign pathogen is achieved without excess inflammation and autoimmunity. In this review, we outline the current knowledge of the CD28 and CTLA-4 signaling mechanisms [involving phosphatidylinositol 3 kinase (PI3K), growth factor receptor-bound protein 2 (Grb2), Filamin A, protein kinase C theta (PKCtheta), and phosphatases] that control T-cell immunity. We also present recent findings on T-cell receptor-interacting molecule (TRIM) regulation of CTLA-4 surface expression, and a signaling pathway involving CTLA-4 activation of PI3K and protein kinase B (PKB)/AKT by which cell survival is ensured under conditions of anergy induction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19426212      PMCID: PMC4186963          DOI: 10.1111/j.1600-065X.2009.00770.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  174 in total

1.  A novel functional interaction between Vav and PKCtheta is required for TCR-induced T cell activation.

Authors:  M Villalba; N Coudronniere; M Deckert; E Teixeiro; P Mas; A Altman
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

2.  CTLA-4-Mediated inhibition of early events of T cell proliferation.

Authors:  M C Brunner; C A Chambers; F K Chan; J Hanke; A Winoto; J P Allison
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

3.  A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling.

Authors:  H Schneider; S da Rocha Dias; H Hu; C E Rudd
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

4.  Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.

Authors:  Jackson G Egen; James P Allison
Journal:  Immunity       Date:  2002-01       Impact factor: 31.745

Review 5.  Regulation of cell growth and differentiation by the colony-stimulating factor 1 receptor.

Authors:  C J Sherr; G V Borzillo; J Kato; S A Shurtleff; J R Downing; M F Roussel
Journal:  Semin Hematol       Date:  1991-04       Impact factor: 3.851

6.  Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

Authors:  J Zha; H Harada; E Yang; J Jockel; S J Korsmeyer
Journal:  Cell       Date:  1996-11-15       Impact factor: 41.582

7.  The MAGUK family protein CARD11 is essential for lymphocyte activation.

Authors:  Hiromitsu Hara; Teiji Wada; Chris Bakal; Ivona Kozieradzki; Shinobu Suzuki; Nobutaka Suzuki; Mai Nghiem; Emily K Griffiths; Connie Krawczyk; Birgit Bauer; Fulvio D'Acquisto; Sankar Ghosh; Wen Chen Yeh; Gottfried Baier; Robert Rottapel; Josef M Penninger
Journal:  Immunity       Date:  2003-06       Impact factor: 31.745

8.  CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin.

Authors:  J H Lai; T H Tan
Journal:  J Biol Chem       Date:  1994-12-02       Impact factor: 5.157

9.  Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function.

Authors:  M Martin; H Schneider; A Azouz; C E Rudd
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

10.  Cytotoxic T lymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes.

Authors:  C M Cilio; M R Daws; A Malashicheva; C L Sentman; D Holmberg
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

View more
  293 in total

Review 1.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

Review 2.  Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.

Authors:  Ayesha Murshid; Jianlin Gong; Mary Ann Stevenson; Stuart K Calderwood
Journal:  Expert Rev Vaccines       Date:  2011-11       Impact factor: 5.217

Review 3.  The regulation and role of T follicular helper cells in immunity.

Authors:  Elissa K Deenick; Cindy S Ma
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

Review 4.  Sustained CD28 expression delays multiple features of replicative senescence in human CD8 T lymphocytes.

Authors:  Stanley T Parish; Jennifer E Wu; Rita B Effros
Journal:  J Clin Immunol       Date:  2010-08-19       Impact factor: 8.317

5.  T-cell signaling and immunopathologies.

Authors:  Christopher E Rudd
Journal:  Semin Immunopathol       Date:  2010-06       Impact factor: 9.623

Review 6.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

Review 7.  Efforts to prevent and halt autoimmune beta cell destruction.

Authors:  Michael J Haller; Mark A Atkinson; Desmond A Schatz
Journal:  Endocrinol Metab Clin North Am       Date:  2010-09       Impact factor: 4.741

8.  Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Ariane Thielens; Aurelien Marabelle; Idit Sagiv-Barfi; Caroline Sola; Fabien Chanuc; Nicolas Fuseri; Cécile Bonnafous; Debra Czerwinski; Amanda Rajapaksa; Erin Waller; Sophie Ugolini; Eric Vivier; François Romagné; Ronald Levy; Mathieu Bléry; Pascale André
Journal:  Blood       Date:  2013-12-10       Impact factor: 22.113

Review 9.  Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors:  Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

Review 10.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.